Drug Testing Industry And Pharmaceutical Company Ask Court To Pause Trump’s Marijuana Rescheduling Move
The National Drug and Alcohol Screening Association and a cannabis-focused biopharmaceutical company filed a motion with a federal appeals court seeking to pause the Trump administration's marijuana rescheduling initiative while litigation challenging the reform is ongoing. The groups argue that cannabis poses significant public health risks, citing concerns about the regulatory change.
Filed under Court Ruling in THC Minnesota's coverage of Minnesota's cannabis and hemp market.
Mentioned
Source Attribution
This summary was compiled from information published by Marijuana Moment. All facts and statements reflect the original source material. For complete details, refer to the original publication.
View Original Source →Related Updates
Trump Is Being Sued For Rescheduling Marijuana By Doctors And A Pharmaceutical Company Who Are ‘Aggrieved’ By The Move
State Attorneys General File Lawsuit To Block Trump Administration’s Marijuana Rescheduling Move
Marijuana Opponents File Lawsuit To Block Trump Administration’s Federal Rescheduling Move
Federal Marijuana Rescheduling Shouldn’t Impact Case On Gun Rights For Users, Trump DOJ Says In Supreme Court Filing
Marijuana Legalization Supporters And Opponents File Notices To Participate In DEA Hearing On Rescheduling Next Month
Marijuana Rescheduling Appeal Process ‘Remains Pending’ Despite Trump’s Executive Order, DEA Says In New Filing
Stay current on Minnesota cannabis
Browse more court ruling updates, the full news feed, or the Minnesota cannabis timeline. Compare products across licensed dispensaries and read our consumer guides.